12/4
03:07 pm
axgn
AxoGen (NASDAQ:AXGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
AxoGen (NASDAQ:AXGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/4
09:08 am
axgn
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
Medium
Report
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
12/4
08:04 am
axgn
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
High
Report
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/3
11:41 pm
axgn
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) [Yahoo! Finance]
Medium
Report
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx) [Yahoo! Finance]
12/3
08:01 pm
axgn
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
Medium
Report
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
12/3
07:57 am
axgn
AxoGen (NASDAQ:AXGN) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Low
Report
AxoGen (NASDAQ:AXGN) was upgraded by analysts at Mizuho to a "strong-buy" rating.
12/1
12:40 pm
axgn
Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen [Seeking Alpha]
Low
Report
Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen [Seeking Alpha]
12/1
07:19 am
axgn
AxoGen (NASDAQ:AXGN) was given a new $40.00 price target on by analysts at Mizuho.
Low
Report
AxoGen (NASDAQ:AXGN) was given a new $40.00 price target on by analysts at Mizuho.
11/14
01:10 pm
axgn
AxoGen (NASDAQ:AXGN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
AxoGen (NASDAQ:AXGN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/4
07:00 am
axgn
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
High
Report
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
10/30
06:43 pm
axgn
Axogen (AXGN): Revenue Forecast to Grow 13.8% Annually Heading Into Earnings Season [Yahoo! Finance]
Low
Report
Axogen (AXGN): Revenue Forecast to Grow 13.8% Annually Heading Into Earnings Season [Yahoo! Finance]
10/30
12:41 pm
axgn
AxoGen (NASDAQ:AXGN) had its price target raised by analysts at HC Wainwright from $25.00 to $26.00. They now have a "buy" rating on the stock.
Low
Report
AxoGen (NASDAQ:AXGN) had its price target raised by analysts at HC Wainwright from $25.00 to $26.00. They now have a "buy" rating on the stock.
10/30
10:40 am
axgn
AxoGen (NASDAQ:AXGN) had its price target raised by analysts at Raymond James Financial, Inc. from $20.00 to $27.00. They now have an "outperform" rating on the stock.
Low
Report
AxoGen (NASDAQ:AXGN) had its price target raised by analysts at Raymond James Financial, Inc. from $20.00 to $27.00. They now have an "outperform" rating on the stock.
10/30
10:06 am
axgn
AxoGen (NASDAQ:AXGN) was given a new $34.00 price target on by analysts at JMP Securities.
Medium
Report
AxoGen (NASDAQ:AXGN) was given a new $34.00 price target on by analysts at JMP Securities.
10/30
09:09 am
axgn
AxoGen (NASDAQ:AXGN) had its price target raised by analysts at Canaccord Genuity Group Inc. from $24.00 to $27.00. They now have a "buy" rating on the stock.
Low
Report
AxoGen (NASDAQ:AXGN) had its price target raised by analysts at Canaccord Genuity Group Inc. from $24.00 to $27.00. They now have a "buy" rating on the stock.
10/30
09:04 am
axgn
AxoGen (NASDAQ:AXGN) had its price target raised by analysts at Citizens Jmp from $26.00 to $34.00. They now have a "market outperform" rating on the stock.
Low
Report
AxoGen (NASDAQ:AXGN) had its price target raised by analysts at Citizens Jmp from $26.00 to $34.00. They now have a "market outperform" rating on the stock.
10/30
07:03 am
axgn
AxoGen (NASDAQ:AXGN) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
AxoGen (NASDAQ:AXGN) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
10/29
08:11 pm
axgn
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
AxoGen (NASDAQ:AXGN) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
10/29
07:00 am
axgn
Axogen, Inc. Reports Third Quarter 2025 Financial Results
High
Report
Axogen, Inc. Reports Third Quarter 2025 Financial Results
10/24
12:16 pm
axgn
AxoGen (NASDAQ:AXGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
AxoGen (NASDAQ:AXGN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/18
10:00 am
axgn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
10/15
07:00 am
axgn
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
Low
Report
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
10/13
01:42 pm
axgn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
10/8
05:44 pm
axgn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
10/5
05:18 am
axgn
A Look at Axogen (AXGN) Valuation Following FDA Avance Delay and Securities Law Probe [Yahoo! Finance]
Medium
Report
A Look at Axogen (AXGN) Valuation Following FDA Avance Delay and Securities Law Probe [Yahoo! Finance]